Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer

Clinical Cancer Research

Volumn 14, Issue 18, 2008, Pages 5785-

  Henić, Emir ^a   Borgfeldt, Christer ^a   Christensen, Ib Jarle ^b   Casslén, Bertil ^a   Høyer Hansen, Gunilla ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CYCLOPHOSPHAMIDE; PACLITAXEL; PLATINUM DERIVATIVE; UROKINASE RECEPTOR; CELL SURFACE RECEPTOR; TUMOR MARKER; UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTORS;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FLUORESCENCE ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY TUMOR; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; BLOOD; EVALUATION; MORTALITY;

CA-125 ANTIGEN; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL;

EID: 53249103673     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0096     Document Type: Article

References (45)

1. Socialstyrelsen, Causes of death 2004, in Statistik, Hälsa och sjukdomar, 2007:1, p. 67.
2. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL. Carcinoma of the ovary. J Epidemiol Biostat 2001;6:107-38.
3. Hakama M, Stenman UH, Knekt P, et al. CA 125 as a screening test for ovarian cancer. J Med Screen 1996; 3:40-2.
4. Jacobs IJ, Skates S, Davies AP, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ 1996; 313:1355-8.
5. Rosenthal AN, Jacobs IJ. The role of CA 125 in screening for ovarian cancer. Int J Biol Markers 1998; 13:216-20.
6. Taylor KJ, Schwartz PE. Screening for early ovarian cancer. Radiology 1994;192:1-10.
7. Tingulstad S, Hagen B, Skjeldestad FE, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol 1996;103:826-31.
8. Woolas RP, Xu FJ, Jacobs IJ, et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 1993;85: 1748-51.
9. Dano K, Behrendt N, Høyer-Hansen G, et al. Plasminogen activation and cancer. Thromb Haemost 2005; 93:676-81.
10. Huai Q, Mazar AP, Kuo A, et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science 2006;311:656-9.
11. Llinas P, Le Du MH, Gȧrdsvoll H, et al. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J 2005;24:1655-63.
12. Behrendt NE, Ronne, Dano K. Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J Biol Chem1996;271:22885-94.
13. Høyer-Hansen G, Behrendt N, Ploug M, Dano K, Preissner KT. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 1997;420:79-85.
14. Sidenius N, Blasi F. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin. FEBS Lett 2000;470: 40-6.
15. Hoyer-Hansen G, Ploug M, Behrendt N, Ronne E, Dano K. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem 1997;243: 21-6.
16. Høyer-Hansen G, Ronne E, Solberg H, et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992;267:18224-9.
17. Bolon I, Zhou HM, Charron Y, Wohfwend A. Vassalli JD. Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression. Am J Pathol 2004;164:2299-304.
18. Zhou HM, Nichols A, Meda P. Vassalli JD. Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J 2000;19:4817-26.
19. Hoyer-Hansen G. Lund IK. Urokinase receptor variants in tissue and body fluids. Adv Clin Chem 2007; 44:65-102.
20. Mustjoki S, Sidenius N, Sier CF, et al. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res 2000;60:7126-32.
21. Piironen T, Laursen B, Pass J, et al. Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor. Clin Chem 2004;50: 2059-68.
22. Wahlberg K, Hoyer-Hansen G. Casslen B. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer. Cancer Res 1998;58:3294-8.
23. Wilhelm OG, WHhelm S, Escort GM, et al. Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol 1999; 180:225-35.
24. Hoyer-Hansen G, Pessara U. Holm A, et al. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. Biochem J 2001; 358:673-9.
25. Kruger A, Soeltl R, Lutz V. et al. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87). Cancer Gene Ther 2000;7:292-9.
26. Lutz V, Reuning U, Krüger A. et al. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice. Biol Chem 2001; 382:789-98.
27. Resnati M, Guttinger M, Valcamonica S. Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996;15:1572-82.
28. Selleri C, Montuori N, Ricci P, et al. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood 2005; 105:2198-205.
29. Riisbro R, Stephens RW, Brunner N, et al. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Gynecol Oncol 2001;82:523-31.
30. Pappot H, Høyer-Hansen G, Rønne E, et al. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer 1997;33:867-72.
31. Stephens RW. Pedersen AN, Nielsen HJ, et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997;43:1868-76.
32. Riisbro R. Christensen IJ, Piironen T, et al. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 2002;8:1132-41.
33. Stephens RW, Nielsen HJ, Christensen IJ, et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999;91:869-74.
34. Borgteldt C, Hansson SR, Gustavsson B, Måsbäck A, Casslén B. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). Int J Cancer 2001;92:497-502. 8
35. Casslen B, Bossmar T, Lecander I, Astedt B. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. Eur J Cancer 1994;30A: 1302-9.
36. Pedersen N, Schmitt M, Rønne E, et al. A ligandfree, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 1993;92:2160-7.
37. Sier CF, Nicoletti I, Santovito ML, et al. Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. Thromb Haemost 2004;91:403-11.
38. Sier CF, Stephens R, Bizik J, et al. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998; 58:1843-9.
39. Borgfeldt C, Bendahl PO, Gustavsson B, et al. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer. Int J Cancer 2003; 107:658-65.
40. Henic E, Sixt M, Hansson S, Hoyer-Hansen G, Casslen B. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor. Gynecol Oncol 2006;101: 28-39.
41. Olson D, Pollanen J, Høyer-Hansen G, et al. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem 1992;267:9129-33.
42. Mol BW, Boll D. De Kanter M, et al. Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models. Gynecol Oncol 2001;80:162-7.
43. Konecny G, Untch M, Pihan A, et al. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin Cancer Res 2001;7:1743-9.
44. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20:1248-59.
45. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B. Survival and prognostic factors in patients with ovarian cancer, Obstet Gynecol 2003;101: 885-91.